| Junping Xu,Hongsheng Yu. Relationship between expression of ER, PR, Her-2, Ki-67 and neoadjuvant chemotherapy effect in breast cancer. Oncol Transl Med, 2014, 13: 220-223. |
| ER、PR、her-2和Ki-67与乳腺癌新辅助化疗治疗疗效的相关性研究 |
| Relationship between expression of ER, PR, Her-2, Ki-67 and neoadjuvant chemotherapy effect in breast cancer |
| |
| DOI： |
| 中文关键词: 乳腺肿瘤； 新辅助化疗；ER、PR、HER-2 和 Ki67； 免疫组化 |
| 英文关键词: breast cancer; neoadjuvant chemotherapy; estrogen receptor (ER); progestogen receptor (PR); human epidermal growth factor receptor (Her-2); Ki-67 |
| 基金项目: |
| Author Name | Affiliation | | Junping Xu | Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao 266003, China | | Hongsheng Yu | Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao 266004, China |
|
| Hits: 9795 |
| Download times: 10480 |
| 中文摘要: |
| 目的 探讨乳腺癌新辅助化疗疗效及ER 、PR、HER2、 Ki67疗效相关性。方法 收集乳腺癌病例 45 例，行TAC方案进行新辅助化疗，采用免疫组化S-P法对化疗前后 ER、PR、HER-2 和 Ki67 的表达进行测定，观察其变化及与疗效间的关系。结果 新辅助化疗后， 完全缓解 7 例( 15.5%) ， 部分缓解 23 例( 51.1%) ， 病情稳定 11例( 24.4%)， 病情发展 4 例( 8.8%) 病理完全缓解3 例( 6.6%)。结论 新辅助化疗前后 ER、PR、HER-2 和 Ki67 表达的变化可作为制定乳腺癌患者后期治疗方案、评估预后的指标。 |
| 英文摘要: |
| Objective: The purpose of the study was to investigate the relationship between the expression of estrogen receptor (ER), progestogen receptor (PR), human epidermal growth factor receptor (Her-2), Ki-67 and the effect of neoadjuvant chemotherapy in breast cancer. Methods: The expression of ER, PR, Her-2 and Ki-67 in 45 breast cancers which received neoadjuvant chemotherapy was detected by immunohistochemistry. Results: The effective rates in ER negative and PR negative groups were higher than those in ER positive and PR positive groups (83.3% vs 59. 4%, 82.4% vs 60.6%). There was no significant difference of the effective rate between Her-2 overexpressed group and Her-2 non-overexpressed group (81.8% vs 64.1%), and the same thing happened between Ki-67 negative group and Ki-67 positive group (67.7% vs 63.2%). Conclusion: In the patients with breast cancer, ER, PR negative ones were more sensitive to neoadjuvant chemotherapy. These patients may get more benefits from chemotherapy. ER, PR could be feasible markers for predicting the effective rate of neoadjuvant chemotherapy. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|